JP2002527496A - 化学化合物 - Google Patents
化学化合物Info
- Publication number
- JP2002527496A JP2002527496A JP2000577136A JP2000577136A JP2002527496A JP 2002527496 A JP2002527496 A JP 2002527496A JP 2000577136 A JP2000577136 A JP 2000577136A JP 2000577136 A JP2000577136 A JP 2000577136A JP 2002527496 A JP2002527496 A JP 2002527496A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- compound according
- phenylthio
- methylpropionic acid
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9822473.6A GB9822473D0 (en) | 1998-10-16 | 1998-10-16 | Chemical compounds |
GB9822473.6 | 1998-10-16 | ||
PCT/GB1999/003420 WO2000023407A2 (fr) | 1998-10-16 | 1999-10-15 | Composes chimiques |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002527496A true JP2002527496A (ja) | 2002-08-27 |
Family
ID=10840605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000577136A Pending JP2002527496A (ja) | 1998-10-16 | 1999-10-15 | 化学化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6306854B1 (fr) |
EP (1) | EP1149063B1 (fr) |
JP (1) | JP2002527496A (fr) |
AT (1) | ATE284853T1 (fr) |
AU (1) | AU6350699A (fr) |
DE (1) | DE69922703T2 (fr) |
ES (1) | ES2235527T3 (fr) |
GB (1) | GB9822473D0 (fr) |
WO (1) | WO2000023407A2 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511785A (ja) * | 2001-12-19 | 2005-04-28 | アストラゼネカ アクチボラグ | PPARαの選択的アンタゴニストとしての3−フェニル−2−アリールアルキルチオプロピオン酸誘導体 |
JP2006503915A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンを用いたx症候群の治療 |
JP2006503917A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンそしてこれらの使用 |
JP2006503916A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダン |
JP2007246474A (ja) * | 2006-03-17 | 2007-09-27 | Mitsubishi Pharma Corp | ベンゼン誘導体 |
WO2007126043A1 (fr) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole |
JPWO2006016637A1 (ja) * | 2004-08-11 | 2008-05-01 | 杏林製薬株式会社 | 新規環状アミノ安息香酸誘導体 |
WO2010064633A1 (fr) * | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | Dérivé d'acide carboxylique comportant un cycle thiazole et ses applications pharmaceutiques |
JP2018517728A (ja) * | 2015-06-15 | 2018-07-05 | ラッシュ・ユニバーシティ・メディカル・センター | 脳由来のPPARαリガンド |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532416A (ja) * | 1998-12-17 | 2002-10-02 | マインドセット・バイオファーマシューティカルズ・(ユーエスエイ)・インコーポレイテッド | 脳のグルコース利用の増進 |
PL361162A1 (en) * | 2000-10-05 | 2004-09-20 | Bayer Aktiengesellschaft | Propionic acid derivatives with ppar-alpha activating properties |
EP1360172A1 (fr) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Agonistes des ppar |
WO2002064130A1 (fr) * | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Composes de recepteurs actives de la proliferation des peroxysomes (ppar) |
US6548538B2 (en) | 2001-05-22 | 2003-04-15 | Bayer Aktiengesellschaft | Propionic acid derivatives |
DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
US7015345B2 (en) * | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
EP1517883B8 (fr) * | 2002-06-20 | 2008-05-21 | AstraZeneca AB | Derives de l'acide benzoique ortho-substitues destines au traitement de l'insulinoresistance |
SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
US7260909B2 (en) * | 2002-10-21 | 2007-08-28 | Sev-Rend Corporation | Separable tag for bags or other containers |
PL378268A1 (pl) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Aktywatory PPAR |
BRPI0407180A (pt) * | 2003-02-14 | 2006-02-07 | Lilly Co Eli | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto |
US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
AR048931A1 (es) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
KR100699928B1 (ko) * | 2004-10-05 | 2007-03-26 | 재단법인서울대학교산학협력재단 | 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법 |
CN101189231B (zh) * | 2005-03-23 | 2011-05-18 | 杏林制药株式会社 | 环状氨基苯基链烷酸衍生物 |
JP2010502719A (ja) | 2006-09-08 | 2010-01-28 | ロード アイランド ホスピタル | アルコール誘発性脳疾患の治療、予防および回復 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018533A1 (fr) | 1994-01-04 | 1995-07-13 | The Trustees Of The University Of Pennsylvania | Procedes et composes exerçant un effet sur la differentiation des adipocytes et sur l'obesite |
AU6773598A (en) * | 1997-03-26 | 1998-10-20 | Institut Pasteur | Treatment of gastrointestinal disease with ppar modulators |
-
1998
- 1998-10-16 GB GBGB9822473.6A patent/GB9822473D0/en not_active Ceased
-
1999
- 1999-10-15 ES ES99950913T patent/ES2235527T3/es not_active Expired - Lifetime
- 1999-10-15 EP EP99950913A patent/EP1149063B1/fr not_active Expired - Lifetime
- 1999-10-15 AU AU63506/99A patent/AU6350699A/en not_active Abandoned
- 1999-10-15 AT AT99950913T patent/ATE284853T1/de not_active IP Right Cessation
- 1999-10-15 WO PCT/GB1999/003420 patent/WO2000023407A2/fr active IP Right Grant
- 1999-10-15 DE DE69922703T patent/DE69922703T2/de not_active Expired - Fee Related
- 1999-10-15 JP JP2000577136A patent/JP2002527496A/ja active Pending
- 1999-10-15 US US09/806,890 patent/US6306854B1/en not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511785A (ja) * | 2001-12-19 | 2005-04-28 | アストラゼネカ アクチボラグ | PPARαの選択的アンタゴニストとしての3−フェニル−2−アリールアルキルチオプロピオン酸誘導体 |
JP2006503915A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンを用いたx症候群の治療 |
JP2006503917A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンそしてこれらの使用 |
JP2006503916A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダン |
JPWO2006016637A1 (ja) * | 2004-08-11 | 2008-05-01 | 杏林製薬株式会社 | 新規環状アミノ安息香酸誘導体 |
JP2007246474A (ja) * | 2006-03-17 | 2007-09-27 | Mitsubishi Pharma Corp | ベンゼン誘導体 |
WO2007126043A1 (fr) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole |
JPWO2007126043A1 (ja) * | 2006-04-27 | 2009-09-10 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
JP5225076B2 (ja) * | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
WO2010064633A1 (fr) * | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | Dérivé d'acide carboxylique comportant un cycle thiazole et ses applications pharmaceutiques |
AU2009323367B2 (en) * | 2008-12-01 | 2013-05-23 | Mitsubishi Tanabe Pharma Corporation | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
US8497382B2 (en) | 2008-12-01 | 2013-07-30 | Mitsubishi Tanabe Pharma Corporation | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
JP2018517728A (ja) * | 2015-06-15 | 2018-07-05 | ラッシュ・ユニバーシティ・メディカル・センター | 脳由来のPPARαリガンド |
US11344524B2 (en) | 2015-06-15 | 2022-05-31 | Rush University Medical Center | Brain derived PPARα ligands |
Also Published As
Publication number | Publication date |
---|---|
DE69922703T2 (de) | 2005-12-08 |
WO2000023407A2 (fr) | 2000-04-27 |
EP1149063B1 (fr) | 2004-12-15 |
EP1149063A2 (fr) | 2001-10-31 |
AU6350699A (en) | 2000-05-08 |
DE69922703D1 (de) | 2005-01-20 |
US6306854B1 (en) | 2001-10-23 |
WO2000023407A3 (fr) | 2000-08-03 |
ES2235527T3 (es) | 2005-07-01 |
ATE284853T1 (de) | 2005-01-15 |
GB9822473D0 (en) | 1998-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002527496A (ja) | 化学化合物 | |
JP6987859B2 (ja) | Magl阻害剤 | |
JP7042547B2 (ja) | Magl阻害剤 | |
JP4906839B2 (ja) | 置換n−スルホニルアミノフェニルエチル−2−フェノキシアセトアミド化合物 | |
JP4521463B2 (ja) | 疼痛の治療に有用なn−(n−スルホニルアミノメチル)シクロプロパンカルボキサミド誘導体 | |
JP4799562B2 (ja) | 置換n−スルホニルアミノベンジル−2−フェノキシアセトアミド化合物 | |
US7214824B2 (en) | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | |
AU2014290411A1 (en) | Sulfonamides as modulators of sodium channels | |
US20110152326A1 (en) | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists | |
TW201307296A (zh) | 可用於治療骨關節炎之新穎咪唑-2-苯甲醯胺化合物 | |
JPS60142932A (ja) | 血小板活性化因子に対するきつ抗体として有用なインデン誘導体 | |
BRPI0608819A2 (pt) | formas cristalinas de um derivado de imidazol | |
EP1389183A1 (fr) | Derives de sulfonamide | |
MX2007016217A (es) | Compuestos de alfa-(aril- o heteroaril-metil)-beta-piperidinopropa namida como antagonista del receptor orl1. | |
US20090227680A1 (en) | Amino Acid Derivatives | |
JP2008543826A (ja) | ORL1−受容体アンタゴニストとしてのα−(アリール−またはヘテロアリール−メチル)−β−ピペリジノプロパン酸化合物 | |
ES2349066T3 (es) | Compuestos de piridilmetilbiciclocarboxamida sustituida. | |
JP2008512384A (ja) | Pparアゴニスト活性を有するフィブラート化合物 | |
US20090286875A1 (en) | Isocystene derivatives for the treatment of pain | |
WO2007052134A1 (fr) | Acide (2s)-2-aminomethyl-5-ethyl heptanoique et son utilisation pharmaceutique | |
JPS615072A (ja) | 新規な3,5−ジ置換1,2,4−オキサジアゾ−ル誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100212 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101217 |